Cargando…

Serum Biomarkers in Differential Diagnosis of Idiopathic Pulmonary Fibrosis and Connective Tissue Disease-Associated Interstitial Lung Disease

Introduction: The goal of this study is to determine whether Advanced glycosylated end-products (AGE), Advanced oxidation protein products (AOPP) and Matrix metalloproteinase 7 (MMP7) could be used as differential biomarkers for idiopathic pulmonary fibrosis (IPF) and connective tissue disease-assoc...

Descripción completa

Detalles Bibliográficos
Autores principales: Cabrera Cesar, Eva, Lopez-Lopez, Lidia, Lara, Estrella, Hidalgo-San Juan, M. Victoria, Parrado Romero, Concepcion, Palencia, Jose Luis Royo Sánchez, Martín-Montañez, Elisa, Garcia-Fernandez, Maria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8307287/
https://www.ncbi.nlm.nih.gov/pubmed/34300333
http://dx.doi.org/10.3390/jcm10143167
_version_ 1783728013866696704
author Cabrera Cesar, Eva
Lopez-Lopez, Lidia
Lara, Estrella
Hidalgo-San Juan, M. Victoria
Parrado Romero, Concepcion
Palencia, Jose Luis Royo Sánchez
Martín-Montañez, Elisa
Garcia-Fernandez, Maria
author_facet Cabrera Cesar, Eva
Lopez-Lopez, Lidia
Lara, Estrella
Hidalgo-San Juan, M. Victoria
Parrado Romero, Concepcion
Palencia, Jose Luis Royo Sánchez
Martín-Montañez, Elisa
Garcia-Fernandez, Maria
author_sort Cabrera Cesar, Eva
collection PubMed
description Introduction: The goal of this study is to determine whether Advanced glycosylated end-products (AGE), Advanced oxidation protein products (AOPP) and Matrix metalloproteinase 7 (MMP7) could be used as differential biomarkers for idiopathic pulmonary fibrosis (IPF) and connective tissue disease-associated interstitial lung disease (CTD-ILD). Method: Seventy-three patients were enrolled: 29 with IPF, 14 with CTD-ILD, and 30 healthy controls. The study included a single visit by participants. A blood sample was drawn and serum was analysed for AGE using spectrofluorimetry, AOPP by spectrophotometry, and MMP7 using sandwich-type enzyme-linked immunosorbent assay. Results: AGE, AOPP and MMP7 serum levels were significantly higher in both IPF and CTD-ILD patients versus healthy controls; and AGE was also significantly elevated in CTD-ILD compared to the IPF group. AGE plasma levels clearly distinguished CTD-ILD patients from healthy participants (AUC = 0.95; 95% IC 0.86–1), whereas in IPF patients, the distinction was moderate (AUC = 0.78; 95% IC 0.60–0.97). Conclusion: In summary, our results provide support for the potential value of serum AGE, AOPP and MMP7 concentrations as diagnostic biomarkers in IPF and CTD-ILD to differentiate between ILD patients and healthy controls. Furthermore, this study provides evidence, for the first time, for the possible use of AGE as a differential diagnostic biomarker to distinguish between IPF and CTD-ILD. The value of these biomarkers as additional tools in a multidisciplinary approach to IPF and CTD-ILD diagnosis needs to be considered and further explored. Multicentre studies are necessary to understand the role of AGE in differential diagnosis.
format Online
Article
Text
id pubmed-8307287
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-83072872021-07-25 Serum Biomarkers in Differential Diagnosis of Idiopathic Pulmonary Fibrosis and Connective Tissue Disease-Associated Interstitial Lung Disease Cabrera Cesar, Eva Lopez-Lopez, Lidia Lara, Estrella Hidalgo-San Juan, M. Victoria Parrado Romero, Concepcion Palencia, Jose Luis Royo Sánchez Martín-Montañez, Elisa Garcia-Fernandez, Maria J Clin Med Article Introduction: The goal of this study is to determine whether Advanced glycosylated end-products (AGE), Advanced oxidation protein products (AOPP) and Matrix metalloproteinase 7 (MMP7) could be used as differential biomarkers for idiopathic pulmonary fibrosis (IPF) and connective tissue disease-associated interstitial lung disease (CTD-ILD). Method: Seventy-three patients were enrolled: 29 with IPF, 14 with CTD-ILD, and 30 healthy controls. The study included a single visit by participants. A blood sample was drawn and serum was analysed for AGE using spectrofluorimetry, AOPP by spectrophotometry, and MMP7 using sandwich-type enzyme-linked immunosorbent assay. Results: AGE, AOPP and MMP7 serum levels were significantly higher in both IPF and CTD-ILD patients versus healthy controls; and AGE was also significantly elevated in CTD-ILD compared to the IPF group. AGE plasma levels clearly distinguished CTD-ILD patients from healthy participants (AUC = 0.95; 95% IC 0.86–1), whereas in IPF patients, the distinction was moderate (AUC = 0.78; 95% IC 0.60–0.97). Conclusion: In summary, our results provide support for the potential value of serum AGE, AOPP and MMP7 concentrations as diagnostic biomarkers in IPF and CTD-ILD to differentiate between ILD patients and healthy controls. Furthermore, this study provides evidence, for the first time, for the possible use of AGE as a differential diagnostic biomarker to distinguish between IPF and CTD-ILD. The value of these biomarkers as additional tools in a multidisciplinary approach to IPF and CTD-ILD diagnosis needs to be considered and further explored. Multicentre studies are necessary to understand the role of AGE in differential diagnosis. MDPI 2021-07-18 /pmc/articles/PMC8307287/ /pubmed/34300333 http://dx.doi.org/10.3390/jcm10143167 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Cabrera Cesar, Eva
Lopez-Lopez, Lidia
Lara, Estrella
Hidalgo-San Juan, M. Victoria
Parrado Romero, Concepcion
Palencia, Jose Luis Royo Sánchez
Martín-Montañez, Elisa
Garcia-Fernandez, Maria
Serum Biomarkers in Differential Diagnosis of Idiopathic Pulmonary Fibrosis and Connective Tissue Disease-Associated Interstitial Lung Disease
title Serum Biomarkers in Differential Diagnosis of Idiopathic Pulmonary Fibrosis and Connective Tissue Disease-Associated Interstitial Lung Disease
title_full Serum Biomarkers in Differential Diagnosis of Idiopathic Pulmonary Fibrosis and Connective Tissue Disease-Associated Interstitial Lung Disease
title_fullStr Serum Biomarkers in Differential Diagnosis of Idiopathic Pulmonary Fibrosis and Connective Tissue Disease-Associated Interstitial Lung Disease
title_full_unstemmed Serum Biomarkers in Differential Diagnosis of Idiopathic Pulmonary Fibrosis and Connective Tissue Disease-Associated Interstitial Lung Disease
title_short Serum Biomarkers in Differential Diagnosis of Idiopathic Pulmonary Fibrosis and Connective Tissue Disease-Associated Interstitial Lung Disease
title_sort serum biomarkers in differential diagnosis of idiopathic pulmonary fibrosis and connective tissue disease-associated interstitial lung disease
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8307287/
https://www.ncbi.nlm.nih.gov/pubmed/34300333
http://dx.doi.org/10.3390/jcm10143167
work_keys_str_mv AT cabreracesareva serumbiomarkersindifferentialdiagnosisofidiopathicpulmonaryfibrosisandconnectivetissuediseaseassociatedinterstitiallungdisease
AT lopezlopezlidia serumbiomarkersindifferentialdiagnosisofidiopathicpulmonaryfibrosisandconnectivetissuediseaseassociatedinterstitiallungdisease
AT laraestrella serumbiomarkersindifferentialdiagnosisofidiopathicpulmonaryfibrosisandconnectivetissuediseaseassociatedinterstitiallungdisease
AT hidalgosanjuanmvictoria serumbiomarkersindifferentialdiagnosisofidiopathicpulmonaryfibrosisandconnectivetissuediseaseassociatedinterstitiallungdisease
AT parradoromeroconcepcion serumbiomarkersindifferentialdiagnosisofidiopathicpulmonaryfibrosisandconnectivetissuediseaseassociatedinterstitiallungdisease
AT palenciajoseluisroyosanchez serumbiomarkersindifferentialdiagnosisofidiopathicpulmonaryfibrosisandconnectivetissuediseaseassociatedinterstitiallungdisease
AT martinmontanezelisa serumbiomarkersindifferentialdiagnosisofidiopathicpulmonaryfibrosisandconnectivetissuediseaseassociatedinterstitiallungdisease
AT garciafernandezmaria serumbiomarkersindifferentialdiagnosisofidiopathicpulmonaryfibrosisandconnectivetissuediseaseassociatedinterstitiallungdisease